KR102196533B1 - Composition of skin external application for penis enlargement - Google Patents
Composition of skin external application for penis enlargement Download PDFInfo
- Publication number
- KR102196533B1 KR102196533B1 KR1020200114386A KR20200114386A KR102196533B1 KR 102196533 B1 KR102196533 B1 KR 102196533B1 KR 1020200114386 A KR1020200114386 A KR 1020200114386A KR 20200114386 A KR20200114386 A KR 20200114386A KR 102196533 B1 KR102196533 B1 KR 102196533B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- weight
- penis
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 210000003899 penis Anatomy 0.000 title claims abstract description 84
- 239000000284 extract Substances 0.000 claims abstract description 108
- 241000545744 Hirudinea Species 0.000 claims abstract description 49
- 244000014603 Kigelia pinnata Species 0.000 claims abstract description 43
- 235000002329 Kigelia pinnata Nutrition 0.000 claims abstract description 43
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 42
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 34
- 229930064664 L-arginine Natural products 0.000 claims abstract description 34
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 28
- 239000006071 cream Substances 0.000 claims description 27
- 229940084038 salix alba bark extract Drugs 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 abstract description 52
- 230000000694 effects Effects 0.000 abstract description 52
- 230000008859 change Effects 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241001278097 Salix alba Species 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010029333 Neurosis Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000002266 amputation Methods 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 208000015238 neurotic disease Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- -1 1.0 wt% Chemical compound 0.000 description 2
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 235000007173 Abies balsamea Nutrition 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 240000000530 Alcea rosea Species 0.000 description 2
- 235000017334 Alcea rosea Nutrition 0.000 description 2
- 235000017303 Althaea rosea Nutrition 0.000 description 2
- 239000004857 Balsam Substances 0.000 description 2
- 240000001548 Camellia japonica Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 244000260524 Chrysanthemum balsamita Species 0.000 description 2
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 206010013883 Dwarfism Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 244000018716 Impatiens biflora Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 240000004674 Papaver rhoeas Species 0.000 description 2
- 235000007846 Papaver rhoeas Nutrition 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 244000181025 Rosa gallica Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 241000722921 Tulipa gesneriana Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000018597 common camellia Nutrition 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 229940105040 geranium extract Drugs 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229940031674 laureth-7 Drugs 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000004200 microcrystalline wax Substances 0.000 description 2
- 235000019808 microcrystalline wax Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DFSJTMFCAJNYBY-BYPYZUCNSA-N N(omega)-nitroso-L-arginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NN=O DFSJTMFCAJNYBY-BYPYZUCNSA-N 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 241001278107 Salix bebbiana Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물을 유효성분으로 포함하는 음경확대용 피부 외용제 조성물에 관한 것이다. 본 발명의 조성물은 혈행개선 및 음경확대 효과가 우수하고, 음경의 탄력성, 발기력 및 강직도 향상 효과를 가지며, 피부에 적용시 자극성이 없어 피부 외용제로서 유용하게 사용될 수 있다.The present invention relates to a composition for external application for skin for penis enlargement comprising L-arginine, leech extract, and sausage tree fruit extract as active ingredients. The composition of the present invention is excellent in improving blood circulation and penis enlargement, has an effect of improving elasticity, erection and stiffness of the penis, and is not irritating when applied to the skin, so it can be usefully used as an external preparation for skin.
Description
본 발명은 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물을 유효성분으로 포함하는 음경확대용 피부 외용제 조성물에 관한 것이다. 본 발명의 조성물은 혈행개선 및 음경확대 효과가 우수하고, 음경의 탄력성, 발기력 및 강직도 향상 효과를 가지며, 피부에 적용시 자극성이 없어 피부 외용제로서 유용하게 사용될 수 있다.The present invention relates to a composition for external application for skin for penis enlargement comprising L-arginine, leech extract, and sausage tree fruit extract as active ingredients. The composition of the present invention is excellent in improving blood circulation and penis enlargement, has an effect of improving elasticity, erection and stiffness of the penis, and is not irritating when applied to the skin, so it can be usefully used as an external preparation for skin.
음경은 만 21세를 전후로 발육이 완성된다. 선천적인 이유나 발육과정에서의 문제로 인해 성년이 되어도 4 cm 이하의 길이를 가지는 경우를 일반적으로 왜소음경증이라고 하며, 의학적 관점에서 정상적인 크기의 음경을 가지고 있으나 실제 음경 크기와 관계없이 자신의 음경 크기에 대한 과소평가 및 타인의 음경 크기에 대한 과대평가로 인해 컴플렉스를 가지는 것을 왜소음경 신경증이라고 한다. The penis is fully developed around the age of 21. A case with a length of 4 cm or less at adulthood due to birth reasons or problems in the development process is generally called dwarf penis. From a medical point of view, a penis of a normal size is found, but the size of the penis is irrespective of the actual size of the penis. Having a complex due to an underestimation of and overestimation of the size of another person's penis is called dwarf penile neurosis.
왜소음경 신경증은 로커룸 컴플렉스라고도 지칭되기도 하는데, 이는 로커룸, 대중 목욕탕 등에서 남자들이 상호간의 음경을 몰래 관찰하며 크기를 비교하게 되는 심리가 있기 때문이다. 이러한 상황에서 자신의 음경을 과소평가하는 경우, 음경이 불가피하게 노출되는 상황, 예를 들어 대중 목욕탕 등의 장소를 기피하게 되고, 이러한 컴플렉스는 음경이 일반적으로 외부에 노출되지 않는 평상시 활동 상황에서의 자신감의 결여 등으로 이어져 사회생활에서 대인 기피증에 시달리는 등 심각한 문제가 발생할 수 있다. 즉, 남성에 있어서 음경의 크기는 단순히 성적인 면에서의 만족감의 향상의 문제로 국한된 것이 아니며, 대인 관계에 있어서의 자신감 상승, 정서적 불만의 해소라는 면에서도 매우 중요한 부분을 차지한다.Dwarf penis neurosis is also referred to as a locker room complex, because there is a psychology in which men secretly observe each other's penis and compare their sizes in locker rooms and public baths. If you underestimate your penis in such a situation, you will avoid situations in which the penis is inevitable, such as public baths, and such complexes are used in normal activities where the penis is not normally exposed to the outside. It can lead to a lack of self-confidence and serious problems, such as suffering from interpersonal avoidance in social life. In other words, in men, the size of the penis is not limited to the problem of simply improving the satisfaction in the sexual aspect, and it occupies a very important part in terms of increasing self-confidence in interpersonal relationships and resolving emotional dissatisfaction.
한편, 음경확대란 인간 남성의 성기 크기를 커지게 하기 위한 다양한 방법들을 의미하며, 상기 방법의 목표는 성기 길이, 두께 및 둘레, 귀두의 크기 등을 증가시키는 것이다. 음경확대는 상기 기술한 음경왜소증 뿐만 아니라 음경왜소 신경증에 있어서도 심리 치료와 함께 행해지고, 음경왜소증 및 음경의 크기로 인해 발생한 심리적 문제를 해결하는 역할을 하며, 실제로 자신감 회복으로 인해 사회생활이 더욱 원활해진 사례들이 존재한다.Meanwhile, penis enlargement refers to various methods for increasing the size of a human male penis, and the goal of the method is to increase the length, thickness and circumference of the penis, and the size of the glans. Penile enlargement is performed in conjunction with psychological treatment not only in the above-described penile dwarfism, but also in penile dwarf neurosis, and plays a role in solving psychological problems caused by penile dwarfism and the size of the penis. Examples exist.
음경의 둘레, 길이 등의 확대를 위한 방법으로는 수술적인 방법 또는 비수술적인 방법이 있다. 수술적인 방법에는 자가 진피 이식, 자가 지방 이식, 대체 진피 이식, 필러 수술, 보형물 삽입술, 현수인대 절단술 등이 있고, 비수술적 방법으로는 감압펌프, 젤크 운동, 견인기구 등을 이용하는 방법이 있다.Methods for enlarging the circumference and length of the penis include a surgical method or a non-surgical method. Surgical methods include autologous dermal transplantation, autologous fat transplantation, replacement dermal transplantation, filler surgery, implant implantation, suspension ligament amputation, and the like, and non-surgical methods include using a decompression pump, a gelk exercise, and a traction device.
수술적 방법 중 상기 자가 진피 이식은 자가 조직을 사용한다는 점에서 조직 거부 반응과 관련된 부작용이 없고 음경의 둘레 확대 효과면에서는 확실하다는 장점이 있으나, 복잡하고 난해한 수술과정으로 인한 통증 및 흉터, 감염, 염증, 피부괴사 등의 단점이 있고, 대체 진피 이식은 비교적 시술이 간편하고 음경의 둘레 확대 효과는 볼 수 있으나, 면역 거부반응, 흉터, 시술 흔적이 남는 등의 단점이 있다. 또한, 체내 불필요한 지방을 이용하여 음경 피하에 이식하는 자가 지방 이식 및 히알루론산 등의 성분을 주입하는 필러 수술은 시술 방식이 간단하나, 자가 지방 이식은 통상적으로 75%의 지방이 체내에서 분해되어 만족할만한 결과를 얻기 힘들고 수술 후 음경 모양의 변형 등의 문제가 있으며, 필러 수술의 경우 약물 주입 표시가 나고 시간경과에 따라 성분이 흡수되어 재시술이 필요하다는 단점이 있다. 또한, 보형물 삽입술은 실리콘 재질의 보형물을 음경 내 이식하는 것으로 이식된 실리콘은 흡수되지 않아 영구적 음경확대효과를 볼 수 있으나, 성관계 등의 물리적 자극 또는 시간 경과에 따른 변형, 예를 들어 보형물의 위치 변경 등의 변형이 올 수 있고, 부자연스러운 모양, 이물감, 비교적 높은 염증 발생률 등의 단점이 있다. 또한, 현수인대 절단술은 현수인대의 절단을 통한 음경확대 방법으로, 발기 전의 음경 길이가 길어지는 효과는 있으나, 발기 후 길이에는 큰 영향을 미치지 않으며, 성기능 장애가 발생할 수 있다는 단점이 있다.Among the surgical methods, the autologous dermal transplantation has the advantage that it does not have side effects related to tissue rejection in that it uses autologous tissue, and it has the advantage of being certain in terms of the effect of expanding the circumference of the penis. There are disadvantages such as inflammation and skin necrosis, and alternative dermal transplantation is relatively easy to perform and has the effect of expanding the circumference of the penis, but has disadvantages such as immune rejection, scars, and traces of the procedure. In addition, autologous fat transplantation, which uses unnecessary fat in the body, and filler surgery that injects components such as hyaluronic acid, is a simple procedure, but autologous fat transplantation is generally satisfactory as 75% of fat is decomposed in the body. It is difficult to obtain possible results, and there is a problem such as deformation of the shape of the penis after surgery. In the case of filler surgery, there is a disadvantage in that a drug injection mark is displayed and components are absorbed over time, requiring a reoperation. In addition, implant implantation is performed by implanting a silicone implant into the penis.Since the implanted silicone is not absorbed, a permanent penis enlargement effect can be seen, but physical stimulation such as sexual intercourse or deformation over time, for example, a change in the position of the implant. Deformation of the back can come, and there are disadvantages such as an unnatural shape, foreign body sensation, and a relatively high incidence of inflammation. In addition, suspension ligament amputation is a penis enlargement method through amputation of the suspension ligament, and has the effect of increasing the length of the penis before erection, but has a disadvantage that it does not significantly affect the length after erection and may cause sexual dysfunction.
비수술적인 방법으로서 음압의 생성으로 음경을 팽창시키고 음경으로 혈액을 끌어들이는 방법을 사용하는 감압펌프는 부적절한 사용 시 음경의 영구적인 손상으로 이어져 발기부전이 발생할 수 있고, 음경의 귀두를 장시간 잡아당기는 장치를 사용하여 음경을 늘리는 견인기구도 음경의 영구적인 손상 문제가 발생할 수 있으며, 짧은 음경을 가진 남성에게만 유의미한 결과를 보였다는 보고도 있어 그 효과의 한계가 존재한다. 또한, 젤크 운동의 경우 상기 감압펌프나 견인기구 대비 음경에 심각한 손상을 일으키기 어려운 안전한 방법이나, 단순히 젤크 운동만으로는 생물학적으로 큰 의미가 없거나 음경의 확대에 전혀 영향을 미치지 못한다는 의견이 있을 정도로 실효성에 의문이 있다.As a non-surgical method, a decompression pump that expands the penis by generating negative pressure and draws blood into the penis can lead to permanent damage to the penis when used improperly, leading to impotence, and pulling the glans of the penis for a long time. A traction device that extends the penis using a device can also cause a problem of permanent penis damage, and there are reports that only men with a short penis have significant results, so there is a limit to its effectiveness. In addition, in the case of gelk exercise, it is a safe method that is difficult to cause serious damage to the penis compared to the above decompression pump or traction device, but it is so effective that there is an opinion that simply gelk exercise has no biological significance or does not affect penis enlargement at all. I have a question.
따라서, 상기 나열된 문제점, 즉, 음경의 손상, 이물감 등의 부작용이 발생하지 않으면서도 효과적으로 음경확대 효과를 나타낼 수 있는 음경확대 기술이 요구되는 실정이다.Accordingly, there is a need for a penis enlargement technique capable of effectively exhibiting a penile enlargement effect without causing side effects such as damage to the penis and foreign body sensation as listed above.
본 발명자들은 상기 종래 기술의 문제점을 인지하고, 음경확대 효과가 우수하면서도 부작용이 최소화된 음경확대용 피부 외용제 조성물을 개발하기 위해 예의 노력한 결과, 특정 성분들의 조합이 시너지 효과로 인해 우수한 음경확대 효과를 나타내면서도 종래의 음경확대를 위한 수술적 또는 비수술적 방법들이 가지는 부작용을 최소화한다는 점을 입증하고 본 발명을 완성하기에 이르렀다.The present inventors recognized the problems of the prior art, and as a result of earnest efforts to develop a skin external preparation composition for penis enlargement that has excellent penis enlargement effect and minimizes side effects, the combination of specific ingredients has an excellent penis enlargement effect due to the synergistic effect. While showing, it was proved that the side effects of conventional surgical or non-surgical methods for penis enlargement were minimized, and the present invention was completed.
본 발명은 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물을 유효성분으로 포함하는 음경확대용 피부 외용제 조성물에 관한 것이다.The present invention relates to a composition for external application for skin for penis enlargement comprising L-arginine, leech extract, and sausage tree fruit extract as active ingredients.
이하 이를 구체적으로 설명한다. 본 발명에서 개시된 다양한 요소들의 모든 조합은 본 발명의 범주에 속한다. 또한 하기의 구체적인 서술에 의해 본 발명 범주가 제한된다고 볼 수 없다.Hereinafter, this will be described in detail. All combinations of the various elements disclosed in the present invention fall within the scope of the present invention. In addition, it cannot be considered that the scope of the present invention is limited by the following specific description.
본 발명은 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물을 유효성분으로 포함하는 혈행개선용 또는 음경확대용 피부 외용제 조성물을 제공한다.The present invention provides a composition for external application for skin for improving blood circulation or penis enlargement, comprising L-arginine, leech extract, and sausage tree fruit extract as active ingredients.
본 발명에서 L-아르기닌(L-arginine)은 아미노산의 일종으로 인체 내에서 일산화질소(NO)를 생성하는 역할을 한다. L-아르기닌에 의해 생성된 일산화질소는 심혈관계, 면역계, 호르몬, 신경계통에 이르기까지 신체에 존재하는 세포의 반응 및 인체에서 발생하는 거의 모든 주요 질병과 직간접적으로 관련되어 있다. 예를 들어, L-아르기닌은 고혈압 예방, 성장 호르몬 분비 촉진으로 인한 노화방지 및 심혈관 질환 개선 효과를 가질 수 있으며, 하이드록시프롤린(hydroxyproline)의 생성을 촉진시켜 콜라겐 형성을 증가시키는 역할을 할 수 있다.In the present invention, L-arginine is a kind of amino acid and serves to produce nitrogen monoxide (NO) in the human body. Nitric oxide produced by L-arginine is directly or indirectly related to the response of cells present in the body to the cardiovascular system, immune system, hormones, nervous system, and almost all major diseases occurring in the human body. For example, L-arginine may have effects of preventing hypertension, preventing aging by promoting the secretion of growth hormone, and improving cardiovascular disease, and may play a role in increasing collagen formation by promoting the production of hydroxyproline. .
본 발명에서 상기 L-아르기닌은 조성물의 총 중량 대비 1 내지 30 중량%로 포함될 수 있으며, 바람직하게는 8 내지 24 중량%로 포함될 수 있다. L-아르기닌이 상기 범위보다 낮은 함량으로 포함되는 경우, 혈행개선 또는 음경확대 효과가 낮거나 없을 수 있으며, 상기 범위를 초과하는 경우, 증가된 함량 대비 증진효과가 낮거나 없을 수 있다.In the present invention, the L-arginine may be included in an amount of 1 to 30% by weight, and preferably 8 to 24% by weight, based on the total weight of the composition. When L-arginine is included in an amount lower than the above range, blood circulation improvement or penis enlargement effect may be low or absent, and when it exceeds the above range, the enhancement effect may be low or absent compared to the increased content.
본 발명에서 거머리(Hirudinea)는 침샘에서 히루딘, 마취물질 등 다양한 생리활성 물질을 분비하는, 환형동물문, 거머리강에 속하는 무척추동물을 의미한다. 상기 히루딘(Hirudin)은 약 60 내지 65가지의 아미노산 조성물로 이루어진 폴리펩타이드로 혈액응고의 억제, 항염, 미세혈관 벽을 자극하고 재생하는 역할을 하며, 마취효과가 있어 특히 민감한 피부에 대한 적합성이 뛰어나다.In the present invention, the leech (Hirudinea) refers to an invertebrate belonging to the annular animal phylum and leech class, which secretes various physiologically active substances such as hirudin and anesthetic substances from the salivary glands. The hirudin is a polypeptide composed of about 60 to 65 amino acids. It inhibits blood coagulation, anti-inflammatory, and stimulates and regenerates the microvascular wall, and has an anesthetic effect, making it particularly suitable for sensitive skin. outstanding.
본 발명에 있어서 거머리 추출물은 추출물을 시중에서 구입하거나 거머리로부터 직접 추출한 추출물일 수 있으며, 종에 제한을 받지 않는다.In the present invention, the leech extract may be an extract obtained from the market or directly extracted from the leech, and is not limited by species.
본 발명에서 상기 거머리 추출물은 조성물의 총 중량 대비 1 내지 30 중량%로 포함될 수 있으며, 바람직하게는 8 내지 24 중량%로 포함될 수 있다. 거머리 추출물이 상기 범위보다 낮은 함량으로 포함되는 경우, 혈행개선 또는 음경확대 효과가 낮거나 없을 수 있으며, 상기 범위를 초과하는 경우, 증가된 함량 대비 증진효과가 낮거나 없을 수 있다.In the present invention, the leech extract may be included in an amount of 1 to 30% by weight, and preferably 8 to 24% by weight, based on the total weight of the composition. When the leech extract is contained in an amount lower than the above range, blood circulation improvement or penis enlargement effect may be low or absent, and when it exceeds the above range, the enhancement effect may be low or absent compared to the increased content.
본 발명에서 소시지트리(Kigelia Africana)는 소시지 모양의 커다란 회색 열매가 달리고 주로 관상용으로 재배되는 아프리카가 원산지인 나무를 의미하며, 소시지트리열매는 상기 소시지트리로부터 수득된 열매를 의미한다. 소시지트리열매에는 플라보노이드 및 사포닌이 풍부하며, 항염, 피부 순환 증가 및 지방 조직을 둘러싼 결합조직에 콜라겐의 합성을 증가시켜 탄력 증강시키는 역할을 한다.In the present invention, the sausage tree (Kigelia Africana) refers to a tree native to Africa where large gray fruits in the shape of a sausage run and grown mainly for ornamental purposes, and the sausage tree fruit refers to a fruit obtained from the sausage tree. Sausage tree fruit is rich in flavonoids and saponins, and plays a role in enhancing elasticity by increasing the synthesis of collagen in the connective tissue surrounding adipose tissue and anti-inflammatory, increasing skin circulation.
본 발명에서 상기 소시지트리열매의 추출물은 조성물의 총 중량 대비 1 내지 30 중량%로 포함될 수 있으며, 바람직하게는 8 내지 24 중량%로 포함될 수 있다. 소시지트리열매 추출물이 상기 범위보다 낮은 함량으로 포함되는 경우, 혈행개선 또는 음경확대 효과가 낮거나 없을 수 있으며, 상기 범위를 초과하는 경우, 증가된 함량 대비 증진효과가 낮거나 없을 수 있다.In the present invention, the extract of the sausage tree fruit may be included in an amount of 1 to 30% by weight, and preferably 8 to 24% by weight, based on the total weight of the composition. When the sausage tree fruit extract is contained in an amount lower than the above range, blood circulation improvement or penis enlargement effect may be low or absent, and when it exceeds the above range, the enhancement effect may be low or absent compared to the increased content.
본 발명에서 추출물은 적절한 추출용매를 사용하여 추출한 결과물을 의미하며, 상기 추출물은 추출로 인해 수득되는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 이들의 조정제물 또는 정제물, 또는 분획물을 포함한다.In the present invention, the extract refers to the result of extraction using an appropriate extraction solvent, and the extract is an extract obtained by extraction, a dilution or concentrate of the extract, a dried product obtained by drying the extract, a prepared product or purified product thereof, or a fraction Includes.
본 발명에 있어서 조성물 내 포함되는 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물은 조성물 전체 중량 대비 30 내지 50 중량%로 포함되는 것일 수 있으며, 바람직하게는 40 중량%로 포함되는 것일 수 있다. In the present invention, the L-arginine, leech extract, and sausage tree fruit extract contained in the composition may be included in an amount of 30 to 50% by weight based on the total weight of the composition, and preferably may be included in an amount of 40% by weight.
L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물이 상기 범위보다 낮은 함량으로 포함되는 경우, 혈행개선 또는 음경확대 효과가 낮거나 없을 수 있으며, 상기 범위를 초과하는 경우, 증가된 함량 대비 증진효과가 낮거나 없을 수 있다.When L-arginine, leech extract, and sausage tree fruit extract are included in an amount lower than the above range, the effect of improving blood circulation or penis enlargement may be low or absent, and when exceeding the above range, the enhancing effect is low compared to the increased content. May or may not.
본 발명에 있어서, 상기 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물은 L-아르기닌:거머리 추출물:소시지트리열매 추출물이 1-3:1-3:1-3의 중량비로 포함되는 것일 수 있으며, 바람직하게는 1:1:1, 2:1:1, 1:2:1, 1:1:2, 2:2:1, 2:1:2, 1:2:2, 3:1:1, 1:3:1 또는 1:1:3의 중량비로 포함되는 것일 수 있으며, 더욱 바람직하게는 1:1:1, 2:1:1, 1:2:1, 2:2:1, 2:1:2, 3:1:1 또는 1:3:1의 중량비로 포함되는 것일 수 있으며, 더더욱 바람직하게는 2:1:1, 2:2:1, 2:1:2 또는 3:1:1의 중량비로 포함되는 것일 수 있으며, 가장 바람직하게는 2:2:1의 중량비로 포함되는 것일 수 있다.In the present invention, the L-arginine, leech extract and sausage tree fruit extract may include L-arginine: leech extract: sausage tree fruit extract in a weight ratio of 1-3:1-3:1-3, Preferably 1:1:1, 2:1:1, 1:2:1, 1:1:2, 2:2:1, 2:1:2, 1:2:2, 3:1:1 , May be included in a weight ratio of 1:3:1 or 1:1:3, more preferably 1:1:1, 2:1:1, 1:2:1, 2:2:1, 2 It may be included in a weight ratio of :1:2, 3:1:1, or 1:3:1, more preferably 2:1:1, 2:2:1, 2:1:2 or 3:1 It may be included in a weight ratio of :1, and most preferably, it may be included in a weight ratio of 2:2:1.
후술하는 실험예에서 나타낸 바와 같이, L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물이 조성물에 상기 기술된 중량비로 포함되는 경우, 혈행개선 및 음경확대 효과가 우수함을 입증하였으며, 나아가 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물이 2:2:1의 중량비로 포함되는 경우 최적의 혈행개선 및 음경확대 효과를 가진다는 점을 입증하였다(표 2 내지 5).As shown in the experimental examples to be described later, when L-arginine, leech extract, and sausage tree fruit extract are included in the composition in the weight ratio described above, it has been proven that the blood circulation improvement and penis enlargement effect are excellent, and further L-arginine, leech When the extract and the sausage tree fruit extract are included in a weight ratio of 2:2:1, it has been demonstrated that they have an optimal blood circulation improvement and penis enlargement effect (Tables 2 to 5).
본 발명의 다른 일 양태에 따르면, 본 발명은 L-아르기닌, 거머리 추출물, 소시지트리열매 추출물 및 흰버드나무껍질 추출물을 유효성분으로 포함하는 혈행개선용 또는 음경확대용 피부 외용제 조성물을 제공한다.According to another aspect of the present invention, the present invention provides a composition for external application for skin for improving blood circulation or penis enlargement, comprising L-arginine, leech extract, sausage tree fruit extract, and white willow bark extract as active ingredients.
본 발명에서 흰버드나무(Salix Alba L.)는 유라시아 지역 및 북부 아프리카의 잿빛의 버드나무로, 연회색의 나뭇잎과 회색 껍질을 가지고 있는 것을 의미한다. 상기 흰버드나무의 껍질에는 아스피린의 전구체인 살리신을 비롯한 여러가지 활성물질이 많이 함유되어 있다. 본 발명에 있어서 흰버드나무 추출물은 껍질로부터 분리된 흰버드나무껍질 추출물일 수 있다.In the present invention, white willow (Salix Alba L.) is a gray willow of Eurasia and northern Africa, which means that it has light gray leaves and gray bark. The bark of the white willow contains many active substances including salicin, a precursor of aspirin. In the present invention, the white willow extract may be a white willow bark extract isolated from the bark.
본 발명에 있어서 상기 흰버드나무껍질 추출물은 조성물 총 중량 대비 2 내지 6 중량%로 포함되는 것일 수 있다. 본 발명의 일 구체예에 따르면 상기 흰버드나무껍질 추출물은 4 중량%로 포함되는 것일 수 있으나 이에 제한되지 않는다.In the present invention, the white willow bark extract may be included in an amount of 2 to 6% by weight based on the total weight of the composition. According to one embodiment of the present invention, the white willow bark extract may be included in 4% by weight, but is not limited thereto.
본 발명에 있어서 상기 L-아르기닌, 거머리 추출물 및 소시지트리열매 혼합물; 및 흰버드나무껍질 추출물은 L-아르기닌, 거머리 추출물 및 소시지트리열매 혼합물:흰버드나무껍질 추출물의 중량비가 25:1 내지 5:1일 수 있으며, 바람직하게는 10:1일 수 있다. 후술하는 실험예에서 나타낸 바와 같이, L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물의 혼합물; 및 흰버드나무껍질 추출물이 조성물에 상기 기술된 중량비로 포함되는 경우, 혈행개선 및 음경확대 효과가 우수함을 입증하였으며, 나아가 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물의 혼합물; 및 흰버드나무껍질 추출물이 10:1의 중량비로 포함되는 경우 최적의 혈행개선 및 음경확대 효과를 가진다는 점을 입증하였다(표 4 및 5).In the present invention, the L-arginine, leech extract and sausage tree fruit mixture; And the white willow bark extract may have a weight ratio of L-arginine, leech extract and sausage tree fruit mixture: white willow bark extract of 25:1 to 5:1, and preferably 10:1. As shown in the experimental examples described below, a mixture of L-arginine, leech extract and sausage tree fruit extract; And when the white willow bark extract is included in the composition at the weight ratio described above, it has proven excellent in improving blood circulation and penis enlargement, and furthermore, a mixture of L-arginine, leech extract and sausage tree fruit extract; And it was proved that the white willow bark extract has an optimal blood circulation improvement and penis enlargement effect when it is included in a weight ratio of 10:1 (Tables 4 and 5).
본 발명에 있어서, 혈행개선용 및 음경확대용 피부 외용제 조성물은 피부에 도포하고 약 10 내지 20분간 마사지 후에 레이저 스페클 대비 이미징 시스템으로 분석 시, 적용 전 미세혈류량 대비 적용 후의 미세혈류량의 변화율이 100% 이상인 것일 수 있으며, 바람직하게는 미세혈류량의 변화율이 150% 이상인 것일 수 있으며, 더욱 바람직하게는 미세혈류량 변화율이 170% 이상인 것일 수 있다. 본 발명의 피부 외용제 조성물은 적용 시 혈류개선 효과가 우수하여 음경의 탄력성, 발기력 및 강직도 향상 효과를 가질 수 있으며, 일시적인 음경확대 효과도 나타낼 수 있다.In the present invention, when the composition for external application for skin for improving blood circulation and for penis enlargement is applied to the skin and massaged for about 10 to 20 minutes, when analyzed by the laser speckle vs. imaging system, the rate of change of the micro blood flow after application compared to the micro blood flow before application is 100 % Or more, preferably, the rate of change of the micro blood flow may be 150% or more, and more preferably, the rate of change of the micro blood flow may be 170% or more. When applied, the composition for external application for skin of the present invention is excellent in improving blood flow, thus improving the elasticity, erection and stiffness of the penis, and can also exhibit a temporary penis enlargement effect.
본 발명의 혈행개선용 및 음경확대용 피부 외용제 조성물은 약학적으로 허용 가능한 첨가제를 더 포함할 수 있다. 본 발명의 약학적으로 허용 가능한 첨가제는 방부제, 증점제, 가소제, 계면활성제, 안정화제, 컨디셔닝제, pH 조절제, 살균보존제, 색소, 향료 등을 포함할 수 있으나 이에 제한되는 것은 아니다. 상기 첨가제의 함량 및 종류는 유효성분의 안정성이나 약효에 영향을 주지 않는 범위 내에서 통상의 기술자가 공지된 범위에서 적절하게 선택할 수 있다. 본 발명의 일 구체예에 따르면, 프로필렌글라이콜 1.5 중량%, 글리세린 2.0 중량%, 페트롤라툼 2.0 중량%, 미네랄오일 3.0 중량%, 글리세릴스테아레이트/피이지-100스테아레이트/피이지-40스테아레이트 3.0 중량%, 세테아릴알코올 3.0 중량%, 마이크로크리스탈린왁스 0.7 중량%, 폴리아크릴아마이드 0.1 중량%, C13-14이소파라핀 1.5 중량%, 카보머 0.2 중량%, 다이소듐이디티에이 0.01 중량%, 소르비탄스테아레이트 0.3 중량%, 소르비탄세스퀴올리에이트 0.3 중량%, 부틸렌글라이콜 3.0 중량%, 1,2-헥산다이올, 1.0 중량%, 라우레스-7 1.0 중량%, 토코페릴아세테이트 1.0 중량%, 프로판다이올 0.5 중량%, 하이드록시아세토페논 0.2 중량%, 다이포타슘글리시리제이트 2.0 중량%, 튤립추출물 0.05 중량%, 모란꽃수 0.05 중량%, 동백나무꽃 추출물 0.05 중량%, 프로방스장미꽃 추출물 0.05 중량%, 데이지꽃 추출물 0.05 중량%, 봉선화꽃/잎/줄기 추출물 0.05 중량%, 복사나무꽃 추출물 0.05 중량%, 접시꽃 추출물 0.05 중량%, 와일드제라늄 추출물 0.05 중량%, 개양귀비꽃잎 추출물 0.05 중량%, 채송화 추출물 0.05 중량%, 향료 미량, 정제수 잔량, 수산화나트륨 적량으로 포함할 수 있으나 이에 제한되지 않는다.The composition for external application for skin for improving blood circulation and for penis enlargement of the present invention may further include a pharmaceutically acceptable additive. Pharmaceutically acceptable additives of the present invention may include preservatives, thickeners, plasticizers, surfactants, stabilizers, conditioning agents, pH adjusters, bactericidal preservatives, pigments, fragrances, etc., but are not limited thereto. The content and type of the additive can be appropriately selected within a range known by a person skilled in the art within a range that does not affect the stability or efficacy of the active ingredient. According to one embodiment of the present invention, propylene glycol 1.5% by weight, glycerin 2.0% by weight, petrolatum 2.0% by weight, mineral oil 3.0% by weight, glyceryl stearate / PEG-100 stearate / PEG-40 Stearate 3.0% by weight, cetearyl alcohol 3.0% by weight, microcrystalline wax 0.7% by weight, polyacrylamide 0.1% by weight, C 13-14 isoparaffin 1.5% by weight, carbomer 0.2% by weight, disodium EDTA 0.01 wt%, sorbitan stearate 0.3 wt%, sorbitan sesquioleate 0.3 wt%, butylene glycol 3.0 wt%, 1,2-hexanediol, 1.0 wt%, laureth-7 1.0 wt%, Tocopheryl acetate 1.0% by weight, propanediol 0.5% by weight, hydroxyacetophenone 0.2% by weight, dipotassium glycyrrhizate 2.0% by weight, tulip extract 0.05% by weight, peony flower water 0.05% by weight, camellia flower extract 0.05% %, Provence rose flower extract 0.05% by weight, daisy flower extract 0.05% by weight, balsam flower/leaf/stem extract 0.05% by weight, radix flower extract 0.05% by weight, hollyhock extract 0.05% by weight, wild geranium extract 0.05% by weight, corn poppy It may include, but is not limited to, 0.05% by weight of petal extract, 0.05% by weight of chapesonghwa extract, a trace amount of fragrance, the remaining amount of purified water, and an appropriate amount of sodium hydroxide.
본 발명에 있어서 혈행개선용 또는 음경확대용 피부 외용제 조성물은 pH가 5.0 내지 7.0 일 수 있으며, 바람직하게는 5.5 내지 6.5일 수 있으며, 더욱 바람직하게는 6.0일 수 있다. 조성물의 pH가 상기 범위보다 낮은 경우, 본 발명의 조성물에 포함된 유효성분의 흡수가 저하되어 혈행개선 또는 음경확대 효과가 미미할 수 있고, 상기 범위보다 높은 경우 피부의 pH 균형이 깨져 피부 민감도가 높아지거나 습진 등의 트러블이 발생할 수 있다.In the present invention, the composition for external application for skin for improving blood circulation or for penis enlargement may have a pH of 5.0 to 7.0, preferably 5.5 to 6.5, and more preferably 6.0. When the pH of the composition is lower than the above range, absorption of the active ingredient contained in the composition of the present invention is lowered, so that the effect of improving blood circulation or penis enlargement may be insignificant, and if it is higher than the above range, the pH balance of the skin is broken and skin sensitivity is increased. Or, it may cause problems such as eczema.
본 발명의 혈행개선용 또는 음경확대용 피부 외용제 조성물은 통상적으로 알려진 제조방법을 이용하여 일반적인 유화 제형 및 가용화 제형 등의 형태로 제조될 수 있다. 예를 들어, 젤류, 크림류, 스프레이류 등의 다양한 제형으로 제조될 수 있으며, 바람직하게는 크림류의 형태로 제조되어 음경에 도포하는 것일 수 있다.The composition for external application for skin for improving blood circulation or for penis enlargement of the present invention may be prepared in the form of a general emulsified formulation and a solubilized formulation using a conventionally known manufacturing method. For example, it may be prepared in a variety of formulations such as gels, creams, sprays, etc., and preferably may be prepared in the form of creams and applied to the penis.
본 발명의 추출물은 당업계에서 통상적으로 사용되는 추출방법을 통해 제조할 수 있다. 예를 들면, 열탕 추출, 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출, 고온가압 추출 등의 방법을 사용할 수 있다. 본 발명의 일 구체예에 따르면, 본 발명의 거머리 추출물, 소시지트리열매 추출물 및 흰버드나무껍질 추출물은 냉침 추출을 통해 추출한다. 상기 원재료로서 자연물에 포함된 활성성분은 열에 의해 변성될 수 있어 고온으로 추출 시 추출 시간 단축될 수는 있으나 추출물 내 포함된 활성성분의 함량이 저하될 수 있다. 따라서 원재료로서 자연물을 사용하는 본 발명의 거머리 추출물, 소시지트리열매 추출물 및 흰버드나무껍질 추출물은 50 내지 90 ℃의 온도에서 추출된 것이 활성성분의 온전성 및 순도 측면에서 매우 유리하다. 본 발명의 일 구체예에 따르면, 본 발명의 추출물은 60 내지 80 ℃의 온도에서 72시간 동안 추출된 것일 수 있다.The extract of the present invention can be prepared through an extraction method commonly used in the art. For example, methods such as hot water extraction, hot water extraction, cold needle extraction, reflux cooling extraction, ultrasonic extraction, high-temperature pressure extraction, and the like can be used. According to one embodiment of the present invention, the leech extract, sausage tree fruit extract, and white willow bark extract of the present invention are extracted through cold chim extraction. As the raw material, the active ingredient contained in the natural substance may be denatured by heat, so that the extraction time may be shortened when extracted at high temperature, but the content of the active ingredient contained in the extract may be reduced. Therefore, the leech extract, sausage tree fruit extract, and white willow bark extract of the present invention using natural substances as raw materials are very advantageous in terms of the integrity and purity of the active ingredient that are extracted at a temperature of 50 to 90°C. According to one embodiment of the present invention, the extract of the present invention may be extracted for 72 hours at a temperature of 60 to 80 ℃.
본 발명의 추출물 제조함에 있어서, 추출용매로 물; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 탄소수 1 내지 4의 저급 알코올; 글리세린, 부틸렌글리콜, 프로필렌글리콜 등의 다가알코올; 클로로포름, 메틸아세테이트, 에틸아세테이트, 벤젠, 헥산, 디에틸에테르, 페트롤륨에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합 형태를 사용할 수 있으며, 바람직하게는 에탄올일 수 있으며, 더욱 바람직하게는 30% 내지 70% (v/v)의 에탄올 수용액일 수 있다.In preparing the extract of the present invention, water as an extraction solvent; Lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propyl alcohol, and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; Hydrocarbon solvents such as chloroform, methyl acetate, ethyl acetate, benzene, hexane, diethyl ether, petroleum ether, and dichloromethane; Alternatively, a mixture thereof may be used, preferably ethanol, and more preferably 30% to 70% (v/v) of an aqueous ethanol solution.
본 발명에 따른 조성물에 포함되는 추출물은 (a) 분쇄기를 통해 원재료를 분쇄하는 단계; (b) 상기 분쇄물의 중량 대비 10배 중량의 70% (v/v) 에탄올 수용액을 분쇄물에 첨가하여 혼합물을 제조하는 단계; (c) 상기 제조된 혼합물을 60 내지 80 ℃에서 72 시간 동안 추출하는 단계; 및 (d) 상기 추출된 결과물을 여과하는 단계;를 포함하는 제조방법을 통해 제조될 수 있다. 또한, 상기 제조방법은 선택적으로, 상기 제조방법에 따라 수득된 여과액을 농축 또는 동결건조하는 단계를 추가로 포함할 수 있다.The extract contained in the composition according to the present invention comprises the steps of: (a) pulverizing the raw material through a pulverizer; (b) preparing a mixture by adding an aqueous solution of 70% (v/v) ethanol 10 times the weight of the pulverized product to the pulverized product; (c) extracting the prepared mixture at 60 to 80° C. for 72 hours; And (d) filtering the extracted resultant; can be prepared through a manufacturing method comprising. In addition, the manufacturing method may optionally further include the step of concentrating or lyophilizing the filtrate obtained according to the manufacturing method.
본 발명에 따른 혈행개선용 또는 음경확대용 피부 외용제 조성물은 피부 또는 음경에 적용 시 우수한 혈행개선, 및 일시적 및/또는 영구적 음경확대 효과를 가지며, 음경의 탄력성 증진, 발기력 향상 및 강직도 향상 효과도 가진다.The composition for external application for skin for improving blood circulation or for penis enlargement according to the present invention has excellent blood circulation improvement and temporary and/or permanent penis enlargement effect when applied to the skin or penis, and also has the effect of enhancing the elasticity of the penis, improving erection and stiffness. .
또한 피부 또는 음경에 적용 시 자극성, 통증, 피부 트러블이 나타나지 않는 등 우수한 안전성을 가지므로 피부 외용제로 유용하게 사용될 수 있다.In addition, when applied to the skin or penis, since it has excellent safety such as no irritation, pain, or skin trouble, it can be used as an external application for skin.
또한 본 발명의 추출물 제조방법에 따르면, 추출과정에서 고온이 사용되지 않아 추출물 내 포함된 활성성분의 온전성을 확보할 수 있다.In addition, according to the extract manufacturing method of the present invention, since high temperatures are not used in the extraction process, the integrity of the active ingredient contained in the extract can be secured.
따라서, 본 발명에 따른 피부 외용제 조성물은 혈행개선 및 음경확대를 위한 피부 외용제 조성물로서 유용성이 우수하다.Accordingly, the composition for external application for skin according to the present invention has excellent usefulness as a composition for external application for skin for improving blood circulation and for penis enlargement.
도 1은 실시예 5의 크림조성물을 사용한 그룹 중 1인의 사용 전/후 미세혈류량의 변화 이미지이다.1 is an image of changes in micro blood flow before/after use of one of the groups using the cream composition of Example 5.
이하 본 발명을 실시예에 의해 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다. 또한, 본 명세서에서 특별히 정의되지 않은 용어들에 대해서는 본 발명이 속하는 기술 분야에서 통상적으로 사용되는 의미를 갖는 것으로 이해되어야 할 것이다.Hereinafter, the present invention will be described in more detail by examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited by these examples. In addition, terms that are not specifically defined in the present specification should be understood as having meanings commonly used in the technical field to which the present invention belongs.
1. 혈행개선 및 음경확대 효과 확인 11. Blood circulation improvement and penis enlargement effect check 1
(1) 거머리 추출물 및 소시지트리열매 추출물의 제조(1) Preparation of leech extract and sausage tree fruit extract
거머리 원재료는 시중에서 구매(구매처: 삼흥건재약업사)하였으며, 상기 건조된 거머리를 잘게 분쇄하여 거머리 분쇄물을 준비하였다. 이후 상기 거머리 분쇄물에 분쇄물의 중량 대비 10배 중량의 70% (v/v) 에탄올 수용액을 첨가하여 혼합한 후, 상기 혼합물을 약 60 내지 80 ℃의 온도에서 72 시간 동안 추출하였다. 이후 상기 추출된 거머리 추출물 용액을 정성 여과지 No.2 (제조사: Whatman)로 여과한 후, 감압 농축기를 이용하여 40 내지 50 ℃에서 농축하고 건조시켜 약 27 g의 거머리 추출물을 수득하였다.The leech raw material was purchased from the market (purchased by Samheung Geonjae Pharmaceutical Co., Ltd.), and the dried leech was pulverized finely to prepare a pulverized leech. Thereafter, a 70% (v/v) aqueous ethanol solution of 10 times the weight of the pulverized product was added to the pulverized leech and mixed, and the mixture was extracted for 72 hours at a temperature of about 60 to 80°C. Thereafter, the extracted leech extract solution was filtered with qualitative filter paper No.2 (manufacturer: Whatman), concentrated at 40 to 50°C using a vacuum concentrator, and dried to obtain about 27 g of leech extract.
소시지트리열매 추출물은 시중에서 구매한 소시지트리열매(구매처: 허브마을)를 원재료로 하여 상기 거머리 추출물 제조방법과 실질적으로 동일한 방법을 통해 제조하였다.Sausage tree fruit extract was prepared by using a commercially purchased sausage tree fruit (purchased from: Herb Village) as a raw material and substantially the same as the leech extract preparation method.
(2) 실시예 1 내지 10 및 비교예 1의 제조(2) Preparation of Examples 1 to 10 and Comparative Example 1
본 발명에 따른 크림조성물을 제조하기 위해 프로필렌글라이콜 1.5 중량%, 글리세린 2.0 중량%, 페트롤라툼 2.0 중량%, 미네랄오일 3.0 중량%, 글리세릴스테아레이트/피이지-100스테아레이트/피이지-40스테아레이트 3.0 중량%, 세테아릴알코올 3.0 중량%, 마이크로크리스탈린왁스 0.7 중량%, 폴리아크릴아마이드 0.1 중량%, C13-14이소파라핀 1.5 중량%, 카보머 0.2 중량%, 다이소듐이디티에이 0.01 중량%, 소르비탄스테아레이트 0.3 중량%, 소르비탄세스퀴올리에이트 0.3 중량%, 부틸렌글라이콜 3.0 중량%, 1,2-헥산다이올, 1.0 중량%, 라우레스-7 1.0 중량%, 토코페릴아세테이트 1.0 중량%, 프로판다이올 0.5 중량%, 하이드록시아세토페논 0.2 중량%, 다이포타슘글리시리제이트 2.0 중량%, 튤립추출물 0.05 중량%, 모란꽃수 0.05 중량%, 동백나무꽃 추출물 0.05 중량%, 프로방스장미꽃 추출물 0.05 중량%, 데이지꽃 추출물 0.05 중량%, 봉선화꽃/잎/줄기 추출물 0.05 중량%, 복사나무꽃 추출물 0.05 중량%, 접시꽃 추출물 0.05 중량%, 와일드제라늄 추출물 0.05 중량%, 개양귀비꽃잎 추출물 0.05 중량%, 채송화 추출물 0.05 중량%, 향료 미량, 정제수 잔량, 수산화나트륨 적량; 및 시중에서 구매한 L-아르기닌, 상기 제조한 거머리 추출물 및 소시지트리열매 추출물을 혼합하였으며, pH가 약 6.0인 실시예 1 내지 10의 크림조성물을 제조하였다. 여기서 상기 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물은 표 1의 중량비에 따라 조성물 중 세개의 추출물을 혼합한 함량이 조성물 총 중량 대비 약 40 중량%가 되도록 하였다. 또한, L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물이 포함되지 않은 크림조성물을 제조하고 이를 비교예 1로 하였다.To prepare the cream composition according to the present invention, propylene glycol 1.5% by weight, glycerin 2.0% by weight, petrolatum 2.0% by weight, mineral oil 3.0% by weight, glyceryl stearate/PG-100 stearate/PG- 40 Stearate 3.0% by weight, cetearyl alcohol 3.0% by weight, microcrystalline wax 0.7% by weight, polyacrylamide 0.1% by weight, C 13-14 isoparaffin 1.5% by weight, carbomer 0.2% by weight, disodium iditi A 0.01 wt%, sorbitan stearate 0.3 wt%, sorbitan sesquioleate 0.3 wt%, butylene glycol 3.0 wt%, 1,2-hexanediol, 1.0 wt%, laureth-7 1.0 wt% , Tocopheryl acetate 1.0% by weight, propanediol 0.5% by weight, hydroxyacetophenone 0.2% by weight, dipotassium glycyrrhizate 2.0% by weight, tulip extract 0.05% by weight, peony flower water 0.05% by weight, camellia flower extract 0.05 Wt%, Provence rose flower extract 0.05 wt%, daisy flower extract 0.05 wt%, balsam flower/leaf/stem extract 0.05 wt%, radix flower extract 0.05 wt%, hollyhock extract 0.05 wt%, wild geranium extract 0.05 wt%, 0.05% by weight of corn poppy petal extract, 0.05% by weight of chapesonghwa extract, trace amount of fragrance, remaining amount of purified water, appropriate amount of sodium hydroxide; And commercially available L-arginine, leech extract and sausage tree fruit extract prepared above were mixed, and the cream compositions of Examples 1 to 10 having a pH of about 6.0 were prepared. Here, the L-arginine, leech extract, and sausage tree fruit extract were made so that the content of the mixture of three extracts in the composition according to the weight ratio in Table 1 was about 40% by weight based on the total weight of the composition. In addition, a cream composition containing no L-arginine, leech extract, and sausage tree fruit extract was prepared, and this was used as Comparative Example 1.
추출물extract
(상기 표는 각 실시예에 있어서 L-아르기닌, 거머리 추출물 및 소시지트리열매의 중량비를 의미한다. 예를 들어, 실시예 1은 L-아르기닌:거머리 추출물:소시지트리열매 추출물이 1:1:1의 중량비를 가진다)(The table above refers to the weight ratio of L-arginine, leech extract, and sausage tree fruit in each example. For example, in Example 1, L-arginine: leech extract: sausage tree fruit extract is 1:1:1 Have a weight ratio of)
(3) 실험예 1. 혈행개선 효과 확인(3) Experimental Example 1. Blood circulation improvement effect confirmation
본 발명 조성물의 혈행개선 효과는 레이저 스페클 대조 분석 기술(Laser speckle contrast technique)에 기초하여 비침습적으로 확인하였다.The effect of improving blood circulation of the composition of the present invention was confirmed non-invasively based on a laser speckle contrast technique.
구체적으로 20 내지 46세의 남성 33명을 대상(타 임상기관과 동시 참여하고 있지 않은 자로 한정)으로 실험이 진행되었으며, 모든 평가는 지원자가 시험부위를 세정한 후 항온항습(22±2℃50±5%) 조건에서 실시하였다. Specifically, the experiment was conducted with 33 males aged 20 to 46 (limited to those not participating at the same time with other clinical institutions), and all evaluations were conducted with constant temperature and humidity (22±2℃50) after the volunteer cleaned the test site. ±5%) conditions.
먼저 전박 부위의 초기 미세혈류량을 레이저 스페클 미세혈류 영상측정기인 moor FLPI-2TM (moor instruments, UK)를 통해 피부 표면에 레드 레이저 빔(red laser beam)을 조사하여 이미지를 획득한 후, 상기 실시예에서 제조한 실시예 1 내지 실시예 10 및 비교예 1의 크림조성물을 각각 3명씩 사용(전박 부위에 도포 후 약 15분간 마사지) 후 moor FLPI-2TM를 통해 레드 레이저 빔을 조사하여 이미지를 획득하였다. First, a red laser beam is irradiated on the skin surface through a laser speckle micro blood flow imager, moor FLPI-2 TM (moor instruments, UK), to obtain an image, and then After using the cream composition of Examples 1 to 10 and Comparative Example 1 prepared in the Examples by 3 people each (applied to the entire skin and massaged for about 15 minutes), the image by irradiating a red laser beam through moor FLPI-2 TM Was obtained.
본 실험에서는 크림조성물의 사용 전/후에 전박 부위를 1분 동안 3초 간격으로 총 20장의 혈행 이미지를 촬영하여 평균값을 분석하였으며, 수학식 1에 따라 계산한 크림조성물 사용 전/후의 미세혈류량 변화율의 평균은 하기 표 2에 나타내었다. 또한 실시예 5의 크림조성물을 사용한 그룹 중 1인의 사용 전/후 미세혈류량의 변화 이미지는 도 1에 나타내었다.In this experiment, a total of 20 blood circulation images were taken at 3 second intervals for 1 minute before and after the use of the cream composition, and the average value was analyzed. The average is shown in Table 2 below. In addition, an image of a change in micro blood flow before and after use of one of the groups using the cream composition of Example 5 is shown in FIG. 1.
[수학식 1][Equation 1]
미세혈류량 변화율(%) = {(크림조성물 사용 후 측정 값의 평균 - 크림조성물 사용 전 측정 값의 평균)/크림조성물 사용 전 측정 값의 평균}x100Rate of change in micro blood flow (%) = {(average of the measured values after using the cream composition-average of the measured values before using the cream composition)/average of the measured values before using the cream composition}x100
상기 표에서 나타난 바와 같이, L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물을 포함하는 본 발명의 크림조성물은 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물을 포함하지 않는 비교예 1 대비 우수한 미세혈류량의 증가율을 나타내는 것을 확인하여 본 발명의 조성물이 우수한 혈류개선 효과를 가진다는 점을 확인할 수 있었다. 특히 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물의 중량비가 2:2:1로 포함된 실시예 5의 경우 미세혈류량의 변화율이 150% 이상으로 상기 유효성분이 다른 중량비로 포함된 실시예 1 내지 4 및 6 내지 10 조성물과 대비해서도 더욱 우수한 혈류개선 효과를 나타내었는데, 이는 동일한 유효성분을 포함되더라도 각각의 유효성분 상호간 비율에 따라 혈류개선 효과가 달라질 수 있음을 의미한다.As shown in the above table, the cream composition of the present invention comprising L-arginine, leech extract and sausage tree fruit extract has excellent micro blood flow compared to Comparative Example 1 that does not contain L-arginine, leech extract and sausage tree fruit extract. By confirming that the increase rate was shown, it was confirmed that the composition of the present invention has an excellent effect of improving blood flow. In particular, in the case of Example 5 in which the weight ratio of L-arginine, leech extract, and sausage tree fruit extract was 2:2:1, the rate of change in micro blood flow was 150% or more, and Examples 1 to 4 in which the active ingredient was included in different weight ratios. And it showed a more excellent blood flow improvement effect compared to the composition of 6 to 10, which means that even if the same active ingredient is included, the effect of improving blood flow may vary according to the ratio between each active ingredient.
(4) 실험예 2. 음경확대 효과 확인(4) Experimental Example 2. Penis enlargement effect confirmation
본 발명의 조성물이 가지는 효과를 확인하기 위하여 지원자 20명을 대상으로 만족도 조사를 수행하였다.In order to confirm the effect of the composition of the present invention, a satisfaction survey was conducted on 20 volunteers.
구체적으로 20명의 지원자에게 상기 실시예 5의 크림조성물을 약 3개월(12주)간 1일 1회, 10분 내지 30분 동안 음경에 도포 후 마사지하는 방법으로 사용하게 하였으며, 4주, 8주 및 12주의 마지막날, 유선상으로 음경확대에 대한 만족도를 5점 평점법(5점: 매우 만족, 4점: 만족, 3점: 보통, 2점: 미흡, 1점: 효과 없음)에 따라 평가하였다. 평가기준은 육안으로 확인할 수 있는 변화가 조금이라도 있는 경우를 3점으로 하였으며, 만족도에 대한 결과는 하기 표 3에 나타내었다.Specifically, 20 volunteers were asked to apply the cream composition of Example 5 to the penis for about 3 months (12 weeks) once a day, for 10 to 30 minutes, and then use it as a massage method. And, on the last day of 12 weeks, satisfaction with penile enlargement by mammary gland was evaluated according to a 5-point scoring method (5 points: very satisfactory, 4 points: satisfactory, 3 points: moderate, 2 points: insufficient, 1 point: no effect). . As for the evaluation criteria, the case where there was any change that can be confirmed by the naked eye was set as 3 points, and the results for the satisfaction are shown in Table 3 below.
상기 표에서 나타난 바와 같이, 본 발명의 크림조성물을 사용한 지원자들의 4주, 8주 및 12주째 수행된 만족도 조사에서 만족도에 대한 평균은 3.35, 3.6 및 3.95로 모두 보통(3점, 육안으로 확인할 수 있는 변화가 있음) 이상의 긍정적인 평가를 받았으며, 효과가 없었다고 답변한 지원자는 없었다.As shown in the table above, in the satisfaction survey conducted at 4 weeks, 8 weeks and 12 weeks of the volunteers who used the cream composition of the present invention, the average of satisfaction was 3.35, 3.6 and 3.95, which were all normal (3 points, can be confirmed with the naked eye. There are changes), and none of the applicants answered that there was no effect.
또한 4주째 만족도 조사에서는 단 2명을 제외하고는 만족도가 보통 이상이었으며, 12주째 만족도 조사에서는 모든 지원자들이 보통 이상의 만족도를 보였다. 특히 12주째 만족도 조사에서 75% 이상의 지원자들이 만족(4점) 이상의 만족도를 보여 본 발명의 조성물이 우수한 음경확대 효과를 가진다는 점을 확인할 수 있었다.In addition, in the satisfaction survey at week 4, the satisfaction was above average except for only two, and in the satisfaction survey at week 12, all applicants showed above average satisfaction. In particular, in the satisfaction survey at week 12, more than 75% of the volunteers showed satisfaction (4 points) or more, confirming that the composition of the present invention had an excellent penis enlargement effect.
또한 지원자들 중 실험기간 내 본 발명의 크림조성물 투여와 관련된 특별한 부작용, 예를 들어 주관적 자극(가려움, 찌르듯이 아픔, 근질거림, 화끈거림, 뻣뻣함, 당김 등) 및 객관적 자극(홍반, 부종, 인설, 구진 등)은 보고되지 않아 본 발명의 조성물이 우수한 안전성을 가진다는 점을 확인하였다.In addition, among volunteers, special side effects related to administration of the cream composition of the present invention during the experiment period, such as subjective stimulation (itch, stabbing pain, itching, burning, stiffness, pulling, etc.) and objective stimulation (erythema, swelling, scales, etc.) , Papules, etc.) were not reported, confirming that the composition of the present invention has excellent safety.
2. 혈행개선 및 음경확대 효과 확인 22. Blood circulation improvement and penis enlargement effect check 2
(1) 흰버드나무껍질 추출물의 제조(1) Preparation of white willow bark extract
흰버드나무껍질 추출물은 시중에서 구매한(구매처: 허브마을) 흰버드나무껍질을 원재료로 하여 상기 목차 1의 거머리 추출물 제조방법과 실질적으로 동일한 방법을 통해 제조하였다.The white willow bark extract was prepared using commercially available white willow bark as a raw material, and substantially the same as the method for preparing leech extract in Table of Contents 1 above.
(2) 실시예 11 및 비교예 2의 제조(2) Preparation of Example 11 and Comparative Example 2
상기 목차 1의 실시예 5 (L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물이 2:2:1의 중량비를 가지며, 조성물 총 중량 대비 약 40 중량%로 포함된 크림조성물)와 동일한 조성에 상기 제조한 흰버드나무껍질 추출물을 조성물 총 중량 대비 4 중량%로 첨가하여 실시예 11의 크림조성물을 제조하였다. 또한 비교예로서 상기 목차 1의 비교예 1과 동일한 조성에 상기 제조한 흰버드나무껍질 추출물을 총 중량 대비 4 중량% 첨가하여 비교예 2의 크림조성물을 제조하였다.The preparation in the same composition as in Example 5 of Table 1 (L-arginine, leech extract, and sausage tree fruit extract have a weight ratio of 2:2:1, and a cream composition containing about 40% by weight based on the total weight of the composition) The cream composition of Example 11 was prepared by adding a white willow bark extract in an amount of 4% by weight based on the total weight of the composition. In addition, as a comparative example, the prepared white willow bark extract was added to the same composition as in Comparative Example 1 in Table of Contents 1 in an amount of 4% by weight based on the total weight to prepare the cream composition of Comparative Example 2.
(3) 실험예 1. 혈행개선 효과 확인(3) Experimental Example 1. Blood circulation improvement effect confirmation
본 발명 조성물의 혈행 개선 효과는 레이저 스페클 대조 분석 기술(Laser speckle contrast technique)에 기초하여 비침습적으로 확인하였다.The effect of improving blood circulation of the composition of the present invention was confirmed non-invasively based on a laser speckle contrast technique.
구체적으로 20 내지 50세의 남성 14명을 대상(타 임상기관과 동시 참여하고 있지 않은 자로 한정)으로 실험이 진행되었으며, 모든 평가는 지원자가 시험부위를 세정한 후 항온항습(22±2℃50±5%) 조건에서 실시하였다.Specifically, the experiment was conducted on 14 males aged 20 to 50 (limited to those not participating at the same time with other clinical institutions), and all evaluations were conducted by the volunteer after washing the test site, followed by constant temperature and humidity (22±2℃50). ±5%) conditions.
먼저 전박 부위의 초기 미세혈류량을 레이저 스페클 미세혈류 영상측정기인 moor FLPI-2TM (moor instruments, UK) 를 통해 피부 표면에 레드 레이저 빔을 조사하고 이미지를 획득한 후, 상기 실시예에서 제조한 실시예 11 및 비교예 2의 크림조성물을 각각 7명씩 사용(전박 부위에 도포 후 약 15분간 마사지) 후 moor FLPI-2TM를 통해 레드 레이저 빔을 조사하고 이미지를 획득하였다.First, a red laser beam was irradiated on the skin surface through the moor FLPI-2 TM (moor instruments, UK), which is a laser speckle micro blood flow imaging device, to obtain an image, and then the initial micro blood flow volume of the forehead region was prepared in the above example. The cream composition of Example 11 and Comparative Example 2 was used by 7 people each (applied to the entire skin and then massaged for about 15 minutes), and then a red laser beam was irradiated through moor FLPI-2 TM to obtain an image.
본 실험에서는 크림조성물의 사용 전/후에 전박 부위를 1분 동안 3초 간격으로 총 20장의 혈행 이미지를 촬영하여 평균값을 분석하였으며, 수학식 1에 따라 계산한 크림조성물 사용 전/후의 미세혈류량 변화율의 평균은 하기 표 4에 나타내었다.In this experiment, a total of 20 blood circulation images were taken at 3 second intervals for 1 minute before/after the use of the cream composition, and the average value was analyzed, and the rate of change in the micro blood flow before/after using the cream composition calculated according to Equation 1 The average is shown in Table 4 below.
상기 표에 나타낸 바와 같이, L-아르기닌, 거머리 추출물, 소시지트리열매 추출물 및 흰버드나무껍질 추출물을 포함하는 본 발명의 크림조성물은 미세혈류량 변화율이 170%로, 흰버드나무껍질 추출물만을 포함하는 비교예 2 대비 우수한 혈행개선 효과를 가진다는 점을 확인하였다. 또한, 흰버드나무껍질 추출물이 포함되지 않은 실시예 5 (표 2, 미세혈류량 변화율 153%) 대비 미세혈류량 변화율이 약 17% 증가하여 유의미한 미세혈류량 변화율을 확인하였다.As shown in the above table, the cream composition of the present invention comprising L-arginine, leech extract, sausage tree fruit extract, and white willow bark extract has a rate of change in micro blood flow of 170%, a comparison comprising only white willow bark extract It was confirmed that it has an excellent effect of improving blood circulation compared to Example 2. In addition, the rate of change of micro blood flow increased by about 17% compared to Example 5 (Table 2, change rate of micro blood flow rate of 153%) in which the white willow bark extract was not included, confirming a significant rate of change of micro blood flow.
(2) 실험예 2. 음경확대 효과 확인(2) Experimental Example 2. Penis enlargement effect confirmation
본 발명의 조성물이 가지는 효과를 확인하기 위하여 지원자 15명을 대상으로 만족도 조사를 수행하였다.In order to confirm the effect of the composition of the present invention, a satisfaction survey was conducted on 15 volunteers.
구체적으로 15명의 지원자에게 상기 실시예 11의 크림조성물을 약 3개월(12주)간 1일 1회, 10분 내지 30분 동안 음경에 도포 후 마사지하는 방법으로 사용하게 하였으며, 4주, 8주 및 12주의 마지막날, 유선상으로 음경확대에 대한 만족도를 5점 평점법(5점: 매우 만족, 4점: 만족, 3점: 보통, 2점: 미흡, 1점: 효과 없음)에 따라 평가하였다. 평가기준은 육안으로 확인할 수 있는 변화가 조금이라도 있는 경우를 3점으로 하였으며, 만족도에 대한 결과는 하기 표에 나타내었다.Specifically, 15 volunteers were asked to apply the cream composition of Example 11 once a day for about 3 months (12 weeks) to the penis for 10 to 30 minutes and then use it as a massage method, 4 weeks and 8 weeks. And, on the last day of 12 weeks, satisfaction with penile enlargement by mammary gland was evaluated according to a 5-point scoring method (5 points: very satisfactory, 4 points: satisfactory, 3 points: moderate, 2 points: insufficient, 1 point: no effect). . As for the evaluation criteria, the case where there was any change that can be confirmed by the naked eye was set as 3 points, and the results for the satisfaction are shown in the table below.
상기 표에서 나타난 바와 같이, 본 발명의 크림조성물을 사용한 지원자들의 4주, 8주 및 12주째 만족도 조사에서 만족도에 대한 평균은 약 3.9, 4.1 및 4.3으로 모두 만족(4점) 이상의 긍정적인 평가를 받았으며, 효과가 미흡(2점) 또는 없었다(1점)고 답변한 지원자는 없었다. 특히 지원자들의 답변에 대한 조사가 시작된 4주째에는 70% 이상의 지원자들이 만족(4점) 이상의 만족도를 보여 본 발명의 조성물이 우수한 음경확대 효과를 가진다는 점을 확인하였다.As shown in the table above, in the satisfaction survey at 4 weeks, 8 weeks, and 12 weeks of the volunteers who used the cream composition of the present invention, the average of satisfaction was about 3.9, 4.1 and 4.3, all of which were satisfied (4 points) or more. No volunteers answered that the effect was insufficient (2 points) or no effect (1 point). In particular, at the 4th week when the survey on the responses of the applicants started, more than 70% of the applicants showed satisfaction (4 points) or higher, confirming that the composition of the present invention had an excellent penis enlargement effect.
또한 지원자들 중 실험기간 내 본 발명의 크림조성물 투여와 관련된 특별한 부작용, 예를 들어 주관적 자극(가려움, 찌르듯이 아픔, 근질거림, 화끈거림, 뻣뻣함, 당김 등) 및 객관적 자극(홍반, 부종, 인설, 구진 등)은 보고되지 않아 본 발명의 조성물이 우수한 안전성을 가진다는 점을 확인하였다.In addition, among volunteers, special side effects related to administration of the cream composition of the present invention during the experiment period, such as subjective stimulation (itch, stabbing pain, itching, burning, stiffness, pulling, etc.) and objective stimulation (erythema, swelling, scales, etc.) , Papules, etc.) were not reported, confirming that the composition of the present invention has excellent safety.
Claims (11)
상기 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물은 조성물 전체 중량 대비 40 중량%로 포함되고,
상기 L-아르기닌, 거머리 추출물 및 소시지트리열매 추출물이 2:2:1의 중량비로 포함되며,
상기 조성물은 pH가 5.5 내지 6.5인, 음경확대용 피부 외용제 조성물.In the skin external preparation composition for penis enlargement comprising L-arginine, leech extract and sausage tree fruit extract as active ingredients,
The L-arginine, leech extract and sausage tree fruit extract are included in 40% by weight based on the total weight of the composition,
The L-arginine, leech extract and sausage tree fruit extract are included in a weight ratio of 2:2:1,
The composition has a pH of 5.5 to 6.5, a composition for external skin for penis enlargement.
상기 조성물은 pH가 6.0인 음경확대용 피부 외용제 조성물.The method of claim 1,
The composition is a composition for external use of skin for penis enlargement with a pH of 6.0.
상기 조성물은 크림류로 제형화 된 것인 음경확대용 피부 외용제 조성물.The method of claim 1,
The composition is formulated as creams for external skin for penis enlargement.
상기 거머리 추출물 및 소시지트리열매 추출물은 하기의 제조방법에 따라 제조된 것인 음경확대용 피부 외용제 조성물.
(a) 분쇄기를 통해 원재료를 분쇄하는 단계;
(b) 상기 분쇄물의 중량 대비 10배 중량의 70% (v/v) 에탄올 수용액을 분쇄물에 첨가하여 혼합물을 제조하는 단계;
(c) 상기 제조된 혼합물을 60 내지 80 ℃에서 72 시간 동안 추출하는 단계; 및
(d) 상기 추출된 결과물을 여과하는 단계The method of claim 1,
The leech extract and the sausage tree fruit extract are prepared according to the following manufacturing method.
(a) grinding the raw material through a grinder;
(b) preparing a mixture by adding an aqueous solution of 70% (v/v) ethanol 10 times the weight of the pulverized product to the pulverized product;
(c) extracting the prepared mixture at 60 to 80° C. for 72 hours; And
(d) filtering the extracted product
상기 조성물은 흰버드나무껍질 추출물을 더 포함하는 것인 음경확대용 피부 외용제 조성물.The method of claim 1,
The composition is a skin external preparation composition for penis enlargement further comprising a white willow bark extract.
상기 흰버드나무껍질 추출물은 조성물의 총 중량 대비 2 내지 6 중량%로 포함되는 것인 음경확대용 피부 외용제 조성물.The method of claim 9,
The white willow bark extract is contained in an amount of 2 to 6% by weight based on the total weight of the composition.
상기 흰버드나무껍질 추출물은 조성물의 총 중량 대비 4 중량%로 포함되는 것인 음경확대용 피부 외용제 조성물.The method of claim 9,
The white willow bark extract is contained in 4% by weight of the total weight of the composition.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200114386A KR102196533B1 (en) | 2020-09-08 | 2020-09-08 | Composition of skin external application for penis enlargement |
| KR1020200181147A KR102371481B1 (en) | 2020-09-08 | 2020-12-22 | Skin external composition for improving penile blood flow |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200114386A KR102196533B1 (en) | 2020-09-08 | 2020-09-08 | Composition of skin external application for penis enlargement |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200181147A Division KR102371481B1 (en) | 2020-09-08 | 2020-12-22 | Skin external composition for improving penile blood flow |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102196533B1 true KR102196533B1 (en) | 2020-12-29 |
Family
ID=74090076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200114386A Active KR102196533B1 (en) | 2020-09-08 | 2020-09-08 | Composition of skin external application for penis enlargement |
| KR1020200181147A Active KR102371481B1 (en) | 2020-09-08 | 2020-12-22 | Skin external composition for improving penile blood flow |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200181147A Active KR102371481B1 (en) | 2020-09-08 | 2020-12-22 | Skin external composition for improving penile blood flow |
Country Status (1)
| Country | Link |
|---|---|
| KR (2) | KR102196533B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102580664B1 (en) | 2023-01-25 | 2023-09-21 | (주)나인팩토리커뮤니케이션 | Composition for topical skin application for feeling of swelling and warmth to the male genital organ, and improving blood circulation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080213407A1 (en) * | 1999-07-01 | 2008-09-04 | Thompson James M | Topical application of L-arginine and menthol to increase penis size |
-
2020
- 2020-09-08 KR KR1020200114386A patent/KR102196533B1/en active Active
- 2020-12-22 KR KR1020200181147A patent/KR102371481B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080213407A1 (en) * | 1999-07-01 | 2008-09-04 | Thompson James M | Topical application of L-arginine and menthol to increase penis size |
Non-Patent Citations (6)
| Title |
|---|
| J. Epidemiol. Community Health August, 65, Suppl 1. P2-534, 2011. * |
| J. Urol., 158, 942-947, 1997 * |
| J. Urol., 158, 942-947, 1997. |
| Natural Product Research., 34(1), 162-166, 2020. * |
| 인용발명 1: J Urol, 158, 942-947, 1997 |
| 인용발명 2: J Epidemiol Community Health August, 65, Suppl 1 P2-534, 2011 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102580664B1 (en) | 2023-01-25 | 2023-09-21 | (주)나인팩토리커뮤니케이션 | Composition for topical skin application for feeling of swelling and warmth to the male genital organ, and improving blood circulation |
| KR102600591B1 (en) | 2023-01-25 | 2023-11-09 | (주)나인팩토리커뮤니케이션 | Composition for topical skin application for feeling of swelling and warmth to the male genital organ, and improving blood circulation |
| KR102600590B1 (en) | 2023-01-25 | 2023-11-09 | (주)나인팩토리커뮤니케이션 | Composition for topical skin application for feeling of swelling and warmth to the male genital organ, and improving blood circulation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102371481B1 (en) | 2022-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Scarpa et al. | Various uses of the castor oil plant (Ricinus communis L.) a review | |
| JPH02117619A (en) | Cosmetic and paramedical compositions | |
| JP5646117B2 (en) | Hair growth promoter and production method | |
| CN108685769A (en) | A kind of herbal mixture black hair anticreep shampoo and preparation method thereof | |
| JP2020504178A (en) | Cosmetic composition comprising a combination of Pongamia oil and 4-t-butylcyclohexanol for treating rosacea | |
| WO2012172199A1 (en) | Composition based on camellia japonica and polygonum hydropiper for protecting the skin | |
| KR101177009B1 (en) | Method of extracting alginic acid and therapeutic composition for atopy using thereof | |
| KR102196533B1 (en) | Composition of skin external application for penis enlargement | |
| KR102071586B1 (en) | Sheet mask pack composition for preventing of sensitive-skin and skin-trouble | |
| CN108056931A (en) | A kind of acne eliminating cream and preparation method thereof | |
| KR102185397B1 (en) | Natural Sopa by using of Artemisia sieversiana Willd with the function of hair loss prevention and hair growth promotion and Manufacturing Method thereof | |
| KR20230139952A (en) | Opuntia humifusa and Hibiseu smanihot-derived plant collagen, method of manufacturing the same and use of the same | |
| CN105106068A (en) | Nerve soothing perfume | |
| JP5047511B2 (en) | Granulocyte-macrophage colony-stimulating factor (GM-CSF) production inhibitor I | |
| CN110339249B (en) | Traditional Chinese medicine composition for treating hemorrhoids and anal fissure as well as preparation method and application thereof | |
| KR102534261B1 (en) | Composition for preventing, improving or treating Striae Distensae comprising Corchorus olitorius L. extract and Taraxacum platycarpum and Hordeum vulgare L. extract | |
| KR102540818B1 (en) | Shampoo for promoting hair growth | |
| US7361373B2 (en) | Antipyrotic and method of manufacturing the same | |
| KR20200118322A (en) | Cleanser for women and methods for manufacturing the same | |
| JP2020152709A (en) | Skin disease therapeutic agent and its manufacturing method | |
| KR102459024B1 (en) | Cosmetic composition comprising mixed extract of verbena hybrida voss, cyclamen persicum mill. and saintpaulia ionantha h. wendl. for moisturizing the skin | |
| KR102071600B1 (en) | Cream composition manufacturing method for preventing of sensitive-skin and skin-trouble | |
| KR102600590B1 (en) | Composition for topical skin application for feeling of swelling and warmth to the male genital organ, and improving blood circulation | |
| KR100754748B1 (en) | 5α-reductase activity inhibiting composition and sebum secretion inhibiting cosmetic composition containing elm extract as an active ingredient | |
| KR100927970B1 (en) | Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20200908 |
|
| PA0201 | Request for examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20200910 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20200908 Patent event code: PA03021R01I Comment text: Patent Application |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20201201 |
|
| A107 | Divisional application of patent | ||
| GRNT | Written decision to grant | ||
| PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20201222 Patent event code: PA01071R01D |
|
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20201222 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20201222 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |